Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
555 Leser
Artikel bewerten:
(2)

Veeva Systems: CARMAT Selects Veeva Vault eTMF to Streamline Clinical Trial Documentation and Processes

Veeva MedTech will enable French medical device company to drive efficiency and improve visibility across its clinical trials

BARCELONA, Spain, Oct. 20, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that CARMAT selected Veeva Vault eTMF to simplify trial master file (TMF) management. By streamlining clinical trial documentation, Vault eTMF will drive efficiency and enable CARMAT with better visibility across its global studies.

Veeva Systems (PRNewsfoto/Veeva Systems)

"As we expand our clinical program, Veeva Vault eTMF will allow us to manage clinical trial documentation and processes digitally, improving our overall efficiency," said Elisabeth Vacher, clinical affairs manager at CARMAT. "Shifting away from paper-based and manual processes gives us valuable time back and allows our clinical operations team to focus on driving trial results and innovation."

CARMAT, the designer and developer of the world's first total bioprosthetic artificial heart, managed study documents manually, resulting in suboptimal visibility and lengthy TMF reviews. Vault eTMF will enable CARMAT to actively manage all TMF processes and documents on a single cloud platform for transparency into the appropriateness of documentation. This will help CARMAT's teams to focus on patients and innovation that can save lives.

"Veeva MedTech is committed to helping medical device and diagnostics companies modernize their systems and processes to speed the delivery of high-quality products to patients," said Seth Goldenberg, vice president, Veeva MedTech. "CARMAT is one of the most innovative emerging medical device manufacturers in Europe, and we're excited to partner with them to help streamline clinical trial operations."

Vault eTMF is part of Veeva Vault Clinical Operations Suite, enabling companies to seamlessly share information and documents across CTMS, eTMF, study start-up, and payments for better collaboration and increased efficiency throughout the study lifecycle.

More medical device companies are turning to Veeva MedTech for unified suites of cloud applications, including the Vault Clinical, Vault Quality, Vault Regulatory, Vault Medical, and Vault Commercial Content Management suites, to manage content, data, and processes through the total product lifecycle.

Additional Information
For more on Veeva MedTech, visit: veeva.com/eu/MedTech
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Contact:




Deivis Mercado

Veeva Systems

925-226-8821

deivis.mercado@veeva.com

Kiran May

Veeva Systems

+44-796-643-2912

kiran.may@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.